Current understanding of the link between angiotensin-converting enzyme and pain perception.

Autor: Bhilare KD; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA., Dobariya P; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA., Hanak F; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA., Rothwell PE; Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA., More SS; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: morex002@umn.edu.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2024 Sep; Vol. 29 (9), pp. 104089. Date of Electronic Publication: 2024 Jul 06.
DOI: 10.1016/j.drudis.2024.104089
Abstrakt: The renin-angiotensin system (RAS) is known to affect diverse physiological processes that affect the functioning of many key organs. Angiotensin-converting enzyme (ACE) modulates a variety of bioactive peptides associated with pain. ACE inhibitors (ACEis) have found applications in the treatment of cardiovascular, kidney, neurological and metabolic disorders. However, ACEis also tend to display undesirable effects, resulting in increased pain sensitization and mechanical allodynia. In this review, we provide comprehensive discussion of preclinical and clinical studies involving the evaluation of various clinically approved ACEis. With the emerging knowledge of additional factors involved in RAS signaling and the indistinct pharmacological role of ACE substrates in pain, extensive studies are still required to elucidate the mechanistic role of ACE in pain perception.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: